Literature DB >> 12411329

CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.

Rowena D Bainton, Jennifer L Byrne, Barbara J Davy, Nigel H Russell.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411329     DOI: 10.1182/blood-2002-08-2398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia.

Authors:  Seok Lee; Si-Hyun Kim; Su-Mi Choi; Dong-Gun Lee; Sung-Yong Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

2.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Authors:  Hui Liu; Xiao Zhai; Zhaoyang Song; Jing Sun; Yang Xiao; Danian Nie; Yu Zhang; Fen Huang; Hongsheng Zhou; Zhiping Fan; Sanfang Tu; Yonghua Li; Xutao Guo; Guopan Yu; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-02-08       Impact factor: 17.388

3.  Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies.

Authors:  Jonathan P Lane; Philippa T G Evans; Zohreh Nademi; Dawn Barge; Anthony Jackson; Sophie Hambleton; Terry J Flood; Andrew J Cant; Mario Abinun; Mary A Slatter; Andrew R Gennery
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-10       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.